Status: Not yet recruiting
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
The study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age).
Participants needed: 740
Trial details
Phase: Phase 3Age: 1-7Biological sex: AllType: InterventionalSponsor: Fidec CorporationUpdated: Jul 24, 2025Locations: 1
Eligibility criteria
Newborn infants of maximum 1 week of age with birth weight > 2,500 g. [+3]
Any confirmed or suspected immunosuppressive or known immunodeficient condition... [+9]